Tysabri

E24936

biologic therapy immunosuppressive agent medication monoclonal antibody

Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.

Try in SPARQL Jump to: Surface forms Statements Referenced by

All labels observed (2)

Label	Occurrences
Tysabri canonical	3
natalizumab	3

Statements (48)

Predicate	Object
instanceOf	biologic therapy ⓘ immunosuppressive agent ⓘ medication ⓘ monoclonal antibody ⓘ
administeredIn	infusion center ⓘ
approvedBy	Food and Drug Administration ⓘ surface form: U.S. Food and Drug Administration
approvedForIndication	inducing and maintaining clinical response in adults with Crohn’s disease ⓘ relapsing forms of multiple sclerosis in adults ⓘ
associatedWithRiskFactor	JC virus antibody positivity ⓘ
belongsToRegimenType	disease-modifying therapy for multiple sclerosis ⓘ
blackBoxWarningFor	progressive multifocal leukoencephalopathy ⓘ
canCause	hepatotoxicity ⓘ hypersensitivity reactions ⓘ opportunistic infections ⓘ progressive multifocal leukoencephalopathy ⓘ
contraindicatedIn	patients with a history of progressive multifocal leukoencephalopathy ⓘ patients with severely compromised immune systems ⓘ
developedBy	Biogen ⓘ Elan Pharmaceuticals ⓘ
hasATCCode	L04AA23 ⓘ
hasDosingInterval	every 4 weeks ⓘ
hasDrugClass	integrin inhibitor ⓘ selective adhesion-molecule inhibitor ⓘ
hasFormulation	concentrate for solution for infusion ⓘ
hasGenericName	Tysabri self-linksurface differs ⓘ surface form: natalizumab
hasHalfLife	approximately 11 days ⓘ
hasMolecularType	humanized monoclonal antibody ⓘ
improves	disability outcomes in some patients with multiple sclerosis ⓘ
indicationRestriction	generally reserved for Crohn’s disease patients who failed or are intolerant to conventional therapies ⓘ generally reserved for patients with inadequate response to other MS therapies ⓘ
isAdministeredBy	healthcare professional ⓘ
isNotIndicatedFor	pediatric multiple sclerosis in many regions ⓘ primary progressive multiple sclerosis ⓘ
isTradeNameOf	Tysabri self-linksurface differs ⓘ surface form: natalizumab
mechanismOfAction	blocks adhesion of leukocytes to vascular endothelium ⓘ reduces migration of immune cells into the central nervous system ⓘ
pregnancyCategory	may pose risk; use only if potential benefit justifies potential risk ⓘ
reduces	formation of new MRI brain lesions in multiple sclerosis ⓘ relapse rate in relapsing multiple sclerosis ⓘ
requiresEnrollmentIn	risk management program for PML ⓘ
requiresMonitoring	liver function tests ⓘ signs and symptoms of progressive multifocal leukoencephalopathy ⓘ
routeOfAdministration	intravenous infusion ⓘ
targets	alpha-4 integrin ⓘ
usedFor	Crohn’s disease ⓘ moderate to severe Crohn’s disease ⓘ relapsing forms of multiple sclerosis ⓘ relapsing-remitting multiple sclerosis ⓘ

How these facts were elicited

The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.

Instruction

You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10.

# Requirements
- If you don't know the subject at all, return an empty list.
- If the subject is not a named entity, return an empty list.
- Include at least one triple where predicate is "instanceOf".
- Do not get too wordy.
- Separate several objects into multiple triples with one object.

Input

Subject: Tysabri
Description of subject: Tysabri is a monoclonal antibody medication primarily used to treat relapsing forms of multiple sclerosis and Crohn’s disease.

Referenced by (6)

Full triples — surface form annotated when it differs from this entity's canonical label.

Biogen → hasProduct → Tysabri ⓘ

Biogen → hasNotableDrug → Tysabri ⓘ

Tysabri → hasGenericName → Tysabri self-linksurface differs ⓘ

this entity surface form: natalizumab

Tysabri → isTradeNameOf → Tysabri self-linksurface differs ⓘ

this entity surface form: natalizumab

relapsing-remitting multiple sclerosis → treatedWith → Tysabri ⓘ

this entity surface form: natalizumab

Elan Pharmaceuticals → developed → Tysabri ⓘ